(Original title: A number of “Qianjintansu” concept stocks fell sharply, Fangsheng Pharmaceutical, North China Pharmaceutical once fell to the limit)
On the 18th, the intraday trend of pharmaceutical stocks was divided, and many individual stocks that had been previously classified as the concept of “Qianjin vinesu” fell sharply. As of press time, North China Pharmaceuticals fell about 9%, Fangsheng Pharmaceuticals fell more than 8%, Buchang Pharmaceuticals fell about 7.5%, Dali Pharmaceuticals fell nearly 7%, and Shuangcheng Pharmaceuticals fell nearly 5%. It is worth noting that North China Pharmaceuticals and Fangsheng Pharmaceuticals once fell by the limit. The Bio Valley once fell by 24%. On May 13 and May 16, the Bio Valley had a “30cm” daily limit for two consecutive days. In addition, the daily limit of Xinhua Pharmaceuticals again, the stock corrected sharply yesterday, closing down 6.29%.
Fangsheng Pharma announced yesterday evening that the company has recently noticed that media reports listed the company as a concept stock of fenugreek. After verification, the company’s 11.60% shareholding subsidiary, Tongtian Bio, has production and sales of fenugreek reference products. The main business is the research, development, production and sales of high-speed countercurrent chromatography (HSCCC), high-purity natural product active ingredient monomers, and natural pharmaceutical raw materials/intermediates. The sales of fenugreek accounted for a small proportion of Tongtian Bio’s operating income. In 2021, the sales revenue of fenugreek in Tongtian Bio was only 2,000 yuan; in the first quarter of 2022, fenugreek did not generate sales revenue. Except for the above circumstances, the company and other subsidiaries currently do not have the research and development, production and sales of fenugreek related products.
North China Pharmaceutical said on the evening of the 16th that recently, the company noticed that some media reports mentioned that “North China Pharmaceutical and the expert team have technical cooperation related to phyllostachys.” According to the company’s verification, at present, the company has not carried out technical cooperation with the relevant expert team, and the company has no related products. In addition, the company has not found other media reports or market rumors that may have a significant impact on the company’s stock trading price,
The company also reminded that in 2021, the company’s operating income was 10.385 billion yuan, a year-on-year decrease of 9.64%; the net profit attributable to shareholders of the listed company was 18.7274 million yuan, a year-on-year decrease of 80.76%. The company achieved operating income of 2.543 billion yuan in the first quarter of 2022, a year-on-year decrease of 6.25%; the net profit attributable to shareholders of the listed company was 13.6817 million yuan. Investors are advised to invest prudently and pay attention to investment risks.
Buchang Pharmaceutical also stated on the evening of the 16th that the company has recently been concerned about media reports listing the company as a concept stock of Qianjin vine. After verification, the company’s wholly-owned subsidiary Shandong Danhong Pharmaceutical Co., Ltd. (formerly Heze Buchang Pharmaceutical Co., Ltd.) owns “A kind of preparation method of fenugreek hydrochloride[专利号：ZL201010556531.0]The company currently has no research and development, production and sales of fenugreek related products. The company has not found other media reports or market rumors that may have a greater impact on the company’s stock trading price, nor has it found any other that may have a significant impact on the company’s stock price. Big information with big impact.
Bio Valley announced on the evening of the 15th that recently, a new drug for the treatment of new crowns discovered by Chinese scientists has been authorized by the national invention patent. The patent specification shows that 10 μM (micromol/L) of fenugreek inhibits the replication of coronavirus by 15,393 times.
The relevant information about the company’s production of Qianjintiansu tablets is as follows: The company obtained the registration approval for Qianjintiansu tablets (Z20026799) on November 16, 2002, and started production and sales in April 2004. Each tablet of this product weighs 0.05g (containing 20mg of fenugreek), and its main function is to clear away heat and cool blood. It is used to treat leukopenia caused by radiotherapy and chemotherapy in tumor patients. Due to the company’s focus on Dengzhanhua series products, it has not continued to produce Qianjintansu tablets since 2004.
Bio Valley also stated that the company has the equipment and technical conditions for the production of Qianjintiansu tablets, and obtained the drug re-registration document on April 28, 2020, and the drug approval number is valid until 2025. Since the product has not been produced and sold in the past two years, when the production is resumed, an application for on-site inspection must be submitted to the Yunnan Provincial Drug Administration.